You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction

Percentage of patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting or at hospital discharge

Date Reviewed: November 19, 2017

Measure Info

MIPS 005NQF 0081CMS 005NQF EndorsedCQMC Core Measure
Measure Type: 
Process
Measure Steward: 
Physician Consortium for Performance Improvement
Clinical Topic Area: 
Heart Failure

Care Setting: 
Home Care
Inpatient
Outpatient
Post-Acute Care
Data Source: 
Electronic Health Records
Registry

ACP supports NQF 0081: “Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction” because there is good evidence that ACE inhibitors and ARBs improve the health of people with heart failure and LVEF < 40%. The measure aligns with current guidelines and represents high-value care for patients with chronic heart failure.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!